-
-
-
The Expanding Benefits of GLP-1 Medicines
Diabetes
Discover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
Top 10 Best-Selling Drugs in Q1 2025
Market Trend
Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
-
-
-
-
鹤岗市|
普兰店市|
迁安市|
通渭县|
宁乡县|
枣强县|
黑水县|
扶余县|
石屏县|
永嘉县|
定安县|
保定市|
黎川县|
叶城县|
和龙市|
惠东县|
且末县|
高碑店市|
邻水|
杭锦旗|
沁阳市|
类乌齐县|
读书|
福建省|
永兴县|
嵩明县|
奇台县|
柏乡县|
东乌珠穆沁旗|
怀仁县|
武义县|
临高县|
琼中|
新民市|
德兴市|
公安县|
小金县|
六枝特区|
吉木萨尔县|
金华市|
来宾市|